Given that next-generation sequencing is widely used in tumor molecular typing to assist in diagnosis and treatment decision-making, clinical research on ARRB1 predicting the efficacy of immune checkpoint inhibitors deserves further exploration. This evidence concerns the gene ARRB1 and neoplasm.